Jaguar Health, Inc. - Common Stock (JAGX)

SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, March 12, 2026 at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com.

Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com

Strengthening balance sheet and capitalization is a key Jaguar priority

As announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized crofelemer drugs - an agreement that is fully aligned with company's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure indications

Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt

Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1, which has the potential to provide Jaguar up to an additional $22M with milestones and other potential future payments

SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, January 15, 2026 at the Lytham Partners Healthcare Investor Summit.

$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions)

Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) on January 1, 2026 that the company has been awarded a $240,000 grant. Canalevia-CA1 is currently conditionally approved for chemotherapy-induced diarrhea (CID) in dogs. The grant will support Jaguar's ongoing study for the treatment of CID in dogs.

SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in October 2025 with the FDA in support of a possible expedited approval pathway

Conditional approval extended through December 2026 for the treatment of CID in dogs

Jaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to register

Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia®

This new IP supports crofelemer's global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelemer - supporting Jaguar's strategy to secure non-dilutive partnership funding

Crofelemer can potentially extend lives of MVID patients - infants and children who face the lethal natural history of the disease

Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVID

Click here to register

Crofelemer can potentially extend and save lives of microvillus inclusion disease patients, reducing the volume of the total parenteral support (PS) necessary for them to survive

Results of ongoing investigator-initiated proof-of-concept trial of crofelemer in United Arab Emirates (UAE) demonstrate disease progression modification and reduction of total parenteral support (PS) in pediatric intestinal failure patients ranging between 12% to 37%

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / October 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 20, 2025, the Company granted 600 restricted stock units (RSUs) to New Employee 1, 600 RSUs to New Employee 2, and 300 RSUs to New Employee 3.

Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support (PS) (comprised of total parenteral nutrition and supplementary IV fluids) of approximately 37%

The two programs are being conducted under separate Single-Patient Investigational New Drug (sIND) applications in the United States

Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally